Pharming Group (NASDAQ:PHAR) Shares Gap Down - Here's Why

Key Points

• Pharming Group's stock gapped down from a closing price of $14.81 to open at $14.13, and was last traded at $13.69 with a trading volume of 8,287 shares.
• Analysts have mixed ratings for Pharming Group, with a consensus average rating of "Hold" and a price target of $30.00.
• The company reported earnings of $0.06 per share, surpassing estimates, and had a revenue of $93.20 million for the previous quarter, significantly exceeding expectations.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) shares gapped down before the market opened on Friday . The stock had previously closed at $14.81, but opened at $14.13. Pharming Group shares last traded at $13.69, with a volume of 8,287 shares.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PHAR. Weiss Ratings restated a "sell (d+)" rating on shares of Pharming Group in a research report on Wednesday, October 8th. Zacks Research cut Pharming Group from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 30th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $30.00.

Pharming Group Price Performance

The stock's fifty day moving average price is $14.23 and its 200-day moving average price is $11.55. The firm has a market cap of $931.80 million, a price-to-earnings ratio of -104.62 and a beta of 0.04. The company has a current ratio of 2.79, a quick ratio of 2.07 and a debt-to-equity ratio of 0.38.

Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.16. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. The firm had revenue of $93.20 million during the quarter, compared to the consensus estimate of $70.36 million. Pharming Group has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC acquired a new stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 2,979 shares of the company's stock, valued at approximately $32,000. 0.03% of the stock is currently owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.